Regulus initiated with a Buy at JonesResearch

JonesResearch initiated coverage of Regulus with a Buy rating and $8 price target. Regulus is an RNA medicine company with upcoming data for lead asset RGLS8429 in autosomal dominant polycystic kidney disease, or ADPKD, notes the analyst. The firm contends that the ADPKD opportunity is “not appreciated at the current share price,” noting that it estimates peak worldwide sales of greater than $1.5B for the indication.